Impact of probucol on xanthoma reduction and its role in cardiovascular event prevention in familial hypercholesterolemia patients

Abstract

Although statins, ezetimibe, and PCSK9 inhibitors effectively reduce LDL-C levels and mitigate CHD risk, some residual risks persist. Probucol, a lipid-lowering agent with potent antioxidant properties, is prescribed in Asia for dyslipidemia treatment, ASCVD prevention, and xanthoma improvement. Its use was discontinued in Western countries due to concerns over HDL-C reduction and QT prolongation; however, recent research supports its therapeutic benefits. Probucol decreases HDL-C by promoting RCT through CETP and SR-BI activation while also enhancing HDL’s antioxidative function by elevating PON1 activity and lowering oxidized HDL levels. Studies on FH patients and those undergoing coronary revascularization indicate its role in secondary CV prevention. An integrated analysis of the PROSPECTIVE and IMPACT on IMT studies has suggested that, despite reducing HDL-C, probucol may offer protective effects against CHD. Potential applications of probucol for other diseases and recent advances of nanoparticle-based probucol delivery systems for the treatment of atherosclerosis and inflammation are also discussed.

Keywords

Probucol / oxidative stress reduction / cholesterol efflux mechanism / CETP activity / high-density lipoprotein / arterial plaque formation

References

[1] Fulcher J,Voysey M.Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.Lancet2015;385:1397-405

[2] Cannon CP,Giugliano RP.Ezetimibe added to statin therapy after acute coronary syndromes.N Engl J Med2015;372:2387-97

[3] Sabatine MS,Keech AC.Evolocumab and clinical outcomes in patients with cardiovascular disease.N Engl J Med2017;376:1713-22

[4] Schwartz GG,Szarek M.Alirocumab and cardiovascular outcomes after acute coronary syndrome.N Engl J Med2018;379:2097-107

[5] Ray KK,Leiter LA.Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol.N Engl J Med2017;376:1430-40

[6] Nissen SE,Brennan D.Bempedoic acid and cardiovascular outcomes in statin-intolerant patients.N Engl J Med2023;388:1353-64

[7] Barnhart JW,McIntosh DD.Hypocholesterolemic effect of 4,4'-(isopropylidenedithio)-bis(2,6-di-t-butylphenol) (probucol).Am J Clin Nutr1970;23:1229-33

[8] Walldius G,Olsson AG.The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST).Am J Cardiol1994;74:875-83

[9] Yamashita S,Harada-Shiba M.Effectiveness and safety of lipid-lowering drug treatments in japanese patients with familial hypercholesterolemia: familial hypercholesterolemia expert forum (FAME) study.J Atheroscler Thromb2022;29:608-38 PMCID:PMC9135647

[10] Rinninger F,Ramakrishnan R,Tall AR.Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism.Arterioscler Thromb Vasc Biol1999;19:1325-32

[11] Hirano K,Tsujii K.Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism.Arterioscler Thromb Vasc Biol2005;25:2422-7

[12] Yamashita S,Matsuzawa Y.Did we abandon probucol too soon?.Curr Opin Lipidol2015;26:304-16

[13] Yamashita S.Where are we with probucol: a new life for an old drug?.Atherosclerosis2009;207:16-23

[14] Matsuzawa Y,Kameda K,Tarui S.Marked hyper-HDL2-cholesterolemia associated with premature corneal opacity. A case report.Atherosclerosis1984;53:207-12

[15] Giammanco A,Barbagallo CM.Hyperalphalipoproteinemia and beyond: the role of HDL in cardiovascular diseases.Life2021;11:581 PMCID:PMC8235218

[16] Hirano K,Nakajima N.Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity.Arterioscler Thromb Vasc Biol1997;17:1053-9

[17] Zhong S,Grove JS.Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.J Clin Invest1996;97:2917-23

[18] Voight BF,Orho-Melander M.Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study.Lancet2012;380:572-80

[19] Robins SJ,Brocia RW,Vasan RS.Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study.Atherosclerosis2013;228:230-6 PMCID:PMC3692011

[20] Ritsch A,Eller P.Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study.Circulation2010;121:366-74

[21] Miller NE.CETP inhibitors and cardiovascular disease: time to think again.F1000Res2014;3:124 PMCID:PMC4149245

[22] Lee DM,Knight-Gibson C.Apolipoprotein-B subclasses as acceptors of cholesteryl esters transferred by CETP.Eur J Clin Invest2008;38:734-42

[23] Nicholls SJ,Ditmarsch M.Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN.Am Heart J2024;274:32-45

[24] Madsen CM,Nordestgaard BG.Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies.Eur Heart J2017;38:2478-86

[25] Hirata A,Sugiyama D.The relationship between very high levels of serum high-density lipoprotein cholesterol and cause-specific mortality in a 20-year follow-up study of japanese general population.J Atheroscler Thromb2016;23:800-9 PMCID:PMC7399265

[26] Hirata A,Watanabe M.Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: the EPOCH-JAPAN study.J Clin Lipidol2018;12:674-84.e5

[27] Barter PJ,Eriksson M.Effects of torcetrapib in patients at high risk for coronary events.N Engl J Med2007;357:2109-22

[28] Kastelein JJ,Burgess L.Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.N Engl J Med2007;356:1620-30

[29] Schwartz GG,Abt M.Effects of dalcetrapib in patients with a recent acute coronary syndrome.N Engl J Med2012;367:2089-99

[30] Lincoff AM,Riesmeyer JS.Evacetrapib and cardiovascular outcomes in high-risk vascular disease.N Engl J Med2017;376:1933-42

[31] Ferri N,Sirtori CR.Present therapeutic role of cholesteryl ester transfer protein inhibitors.Pharmacol Res2018;128:29-41

[32] Forrest MJ,Briscoe RJ.Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.Br J Pharmacol2008;154:1465-73

[33] Bowman L,Chen F.Effects of anacetrapib in patients with atherosclerotic vascular disease.N Engl J Med2017;377:1217-27

[34] Krishna R,Liu Y.Chronic administration of anacetrapib is associated with accumulation in adipose and slow elimination.Clin Pharmacol Ther2017;102:832-40

[35] Yamashita S,Macchi C,Matsuzawa Y.Cholesteryl ester transfer protein: an enigmatic pharmacology - Antagonists and agonists.Atherosclerosis2018;278:286-98

[36] Buckley MM,Price AH.Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia.Drugs1989;37:761-800

[37] Tawara K,Abiko Y.Mode of action of probucol in reducing serum cholesterol in mice.Jpn J Pharmacol1986;40:123-33

[38] Naruszewicz M,Pittman RC.A novel mechanism by which probucol lowers low density lipoprotein levels demonstrated in the LDL receptor-deficient rabbit.J Lipid Res1984;25:1206-13

[39] Baker SG,Mendelsohn D.Treatment of homozygous familial hypercholesterolaemia with probucol.S Afr Med J1982;62:7-11

[40] Matsuzawa Y,Funahashi T,Tarui S.Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer.Am J Cardiol1988;62:66B-72B

[41] Durrington PN.Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemia.Atherosclerosis1985;55:187-94

[42] Sanjurjo P,Sasieta M,Ariza F.Treatment with probucol of children with familial hypercholesterolaemia.Acta Paediatr Scand1988;77:132-5

[43] Quach D,La FM.Cell lipid metabolism modulators 2-bromopalmitate, D609, monensin, U18666A and probucol shift discoidal HDL formation to the smaller-sized particles: implications for the mechanism of HDL assembly.Biochim Biophys Acta2016;1861:1968-79

[44] Chapman MJ,Guerin M.Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.Eur Heart J2010;31:149-64 PMCID:PMC2806550

[45] Bagdade JD,Subbaiah PV.Accelerated cholesteryl ester transfer in plasma of patients with hypercholesterolemia.J Clin Invest1991;87:1259-65 PMCID:PMC295149

[46] Bagdade JD,Ritter MC.Probucol treatment in hypercholesterolemic patients: effects on lipoprotein composition, HDL particle size, and cholesteryl ester transfer.Atherosclerosis1990;84:145-54

[47] Cao J,Li F,Fan D.Protein markers of dysfunctional HDL in scavenger receptor class B type I deficient mice.J Transl Med2018;16:155 PMCID:PMC5992774

[48] McPherson R,Milne RW,Marcel YL.Increase in plasma cholesteryl ester transfer protein during probucol treatment. Relation to changes in high density lipoprotein composition.Arterioscler Thromb1991;11:476-81

[49] Chiesa G,Cassinotti M.Mechanisms of high-density lipoprotein reduction after probucol treatment: changes in plasma cholesterol esterification/transfer and lipase activities.Metabolism1993;42:229-35

[50] Ishigami M,Sakai N.High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins.Eur J Clin Invest1997;27:285-92

[51] Adlouni A,Saïle R,Fruchart J.Probucol promotes reverse cholesterol transport in heterozygous familial hypercholesterolemia. Effects on apolipoprotein AI-containing lipoprotein particles.Atherosclerosis2000;152:433-40

[52] Yamamoto A,Yokoyama S,Yamamura T.Effects of probucol on xanthomata regression in familial hypercholesterolemia.Am J Cardiol1986;57:29H-35H

[53] Fujita M.A comparative study of the therapeutic effect of probucol and pravastatin on xanthelasma.J Dermatol1996;23:598-602

[54] Miida T,Miyazaki O.Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling.Atherosclerosis2008;200:329-35

[55] Favari E,Zimetti F,Bernini F.Probucol inhibits ABCA1-mediated cellular lipid efflux.Arterioscler Thromb Vasc Biol2004;24:2345-50

[56] Yakushiji E,Nishida T.Probucol-oxidized products, spiroquinone and diphenoquinone, promote reverse cholesterol transport in mice.Arterioscler Thromb Vasc Biol2016;36:591-7

[57] Hafiane A,Ronca A,Kiss RS.Probucol treatment is associated with an ABCA1-independent mechanism of cholesterol efflux to lipid poor apolipoproteins from foam cell macrophages.BBA Adv2021;1:100003 PMCID:PMC10074979

[58] Hafiane A,Kiss RS.High density lipoprotein-based therapeutics: novel mechanism of probucol in foam cells.Front Cardiovasc Med2022;9:895031 PMCID:PMC9086955

[59] Hoekstra M.Probucol-induced hypocholesterolemia is not associated with exacerbated foam cell formation in ABCG1 knockout mice.Atherosclerosis2020;296:91-2

[60] Miida T,Tsuda T.High prebeta1-HDL levels in hypercholesterolemia are maintained by probucol but reduced by a low-cholesterol diet.Atherosclerosis1998;138:129-34

[61] Hong SC,Wu ZH.Effect of probucol on HDL metabolism and class B type I scavenger receptor (SR-BI) expression in the liver of hypercholesterolemic rabbits.Int J Cardiol2007;115:29-35

[62] Cristol LS,Grundy SM.Effect of low-dose probucol therapy on LDL oxidation and the plasma lipoprotein profile in male volunteers.Atherosclerosis1992;97:11-20

[63] Kaminnyi AI,Perepelitsa EI.Relationship between free-radical lipid oxidation and efficiency of coronary angioplasty in coronary patients.Bull Exp Biol Med2007;144:664-6

[64] Carew TE,Steinberg D.Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit.Proc Natl Acad Sci USA1987;84:7725-9 PMCID:PMC299373

[65] Kita T,Ishii K.The role of oxidized lipoproteins in the pathogenesis of atherosclerosis.Clin Exp Pharmacol Physiol Suppl1992;20:37-42.

[66] Guo YS,Cao J.Antioxidant and lipid-regulating effects of probucol combined with atorvastatin in patients with acute coronary syndrome.J Thorac Dis2015;7:368-75

[67] Smith JD.Dysfunctional HDL as a diagnostic and therapeutic target.Arterioscler Thromb Vasc Biol2010;30:151-5 PMCID:PMC2809786

[68] Noto H,Hashimoto Y.Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency.Atherosclerosis2003;171:131-6

[69] Hong SC,Wu ZH.Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits.J Cardiovasc Pharmacol2006;47:77-81

[70] Inagaki M,Nishida M.Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia.J Atheroscler Thromb2012;19:643-56

[71] Yao S,Zhao L.Oxidized high density lipoprotein induces macrophage apoptosis via toll-like receptor 4-dependent CHOP pathway.J Lipid Res2017;58:164-77

[72] Okada T,Ohama T.Development and clinical application of an enzyme-linked immunosorbent assay for oxidized high-density lipoprotein.J Atheroscler Thromb2021;28:703-15 PMCID:PMC8265427

[73] Kita T,Yokode M.Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.Proc Natl Acad Sci USA1987;84:5928-31 PMCID:PMC298976

[74] Niimi M,Nozako M.Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits.Lipids Health Dis2013;12:166

[75] Li S,Niimi M.Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits.J Atheroscler Thromb2014;21:648-58

[76] Chen C,Cao Y.Mechanisms underlying the inhibitory effects of probucol on elastase-induced abdominal aortic aneurysm in mice.Br J Pharmacol2020;177:204-16 PMCID:PMC6976779

[77] Li Y,Cao Y.Probucol decreases homocysteine-stimulated CRP production in rat aortic smooth muscle cells via regulating HO-1/NADPH oxidase/ROS/p38 pathway.Acta Biochim Biophys Sin2021;53:212-9

[78] Ko YG,Chol Kang W,Wook Kim S.Effects of combination therapy with cilostazol and probucol versus monotherapy with cilostazol on coronary plaque, lipid and biomarkers: SECURE study, a double-blind randomized controlled clinical trial.J Atheroscler Thromb2014;21:816-30

[79] Sawayama Y,Maeda N.Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST).J Am Coll Cardiol2002;39:610-6

[80] Yamashita S,Arai H.Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan.J Atheroscler Thromb2008;15:292-303

[81] Kasai T,Kubota N,Amano A.Probucol therapy improves long-term (>10-year) survival after complete revascularization: a propensity analysis.Atherosclerosis2012;220:463-9

[82] Yamashita S,Ohama T.Rationale and design of the PROSPECTIVE trial: probucol trial for secondary prevention of atherosclerotic events in patients with prior coronary heart disease.J Atheroscler Thromb2016;23:746-56 PMCID:PMC7399286

[83] Yamashita S,Bujo H.Probucol trial for secondary prevention of atherosclerotic events in patients with coronary heart disease (PROSPECTIVE).J Atheroscler Thromb2021;28:103-23 PMCID:PMC7957028

[84] Kang HJ,Sung J.Effect of probucol and/or cilostazol on carotid intima media thickness in patients with coronary heart disease: a randomized, multicenter, multinational study.J Atheroscler Thromb2021;28:124-36 PMCID:PMC7957030

[85] Arai H,Masuda D.Integrated analysis of two probucol trials for the secondary prevention of atherosclerotic cardiovascular events: PROSPECTIVE and IMPACT.J Atheroscler Thromb2022;29:850-65 PMCID:PMC9174092

[86] Hong KS,Lee JY.PICASSO InvestigatorsRationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: a randomized controlled trial.Int J Stroke2015;10:1153-8

[87] Kim BJ,Kwon SU.Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial.Lancet Neurol2018;17:509-18

[88] Seo WK,Lee J.PICASSO InvestigatorsDesign and rationale of the intima-medial thickness sub-study of the prevention of CArdiovascular events in iSchemic stroke patients with high risk of cerebral hemOrrhage (PICASSO-IMT) study.J Stroke Cerebrovasc Dis2017;26:1892-8

[89] Setsuda M,Hiraoka N.Probucol therapy in the prevention of restenosis after successful percutaneous transluminal coronary angioplasty.Clin Ther1993;15:374-382.

[90] Tardif JC,Lespérance J.Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group.N Engl J Med1997;337:365-72

[91] Côté G,Lespérance J.Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group.Circulation1999;99:30-5

[92] Daida H,Yokoi H.Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial [PART]).Am J Cardiol2000;86:550-2, A9

[93] Liu J,Lu H.Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis.PLoS One2015;10:e0124021 PMCID:PMC4405356

[94] Harada Y,Kufner S.Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.Cardiovasc Diabetol2016;15:124 PMCID:PMC5009646

[95] Kufner S,Mehilli J.Randomized trial of polymer-free sirolimus- and probucol-eluting stents versus durable polymer zotarolimus-eluting stents: 5-year results of the ISAR-TEST-5 trial.JACC Cardiovasc Interv2016;9:784-92

[96] Zuhdi AS, Krackhardt F, Waliszewski MW, Ismail MD, Boxberger M, Wan Ahmad WA. Efficacy and safety of polymer-free ultrathin strut sirolimus-probucol coated drug-eluting stents for chronic total occlusions: insights from the coroflex ISAR 2000 worldwide registry.Cardiol Res Pract2018;2018:8053168 PMCID:PMC5852858

[97] Chen KQ,Cheng L,Wang ZB.Research and progress of probucol in nonalcoholic fatty liver disease.Mini Rev Med Chem2023;23:1905-11

[98] Cui X,Wang H.Preventing contrast-induced acute kidney injury with probucol and hydration in patients with coronary heart disease: a systematic review and meta-analysis of randomized controlled trials.Medicine2023;102:e33273

[99] Navarese EP,Andreotti F.Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis.PLoS One2017;12:e0168726 PMCID:PMC5289438

[100] Pranata R,Vania R.The role of probucol preventing contrast-induced nephropathy in patients undergoing invasive coronary procedures - Systematic review and meta-analysis of randomized controlled trials.Turk Kardiyol Dern Ars2021;49:51-9

[101] Sharif A,Lam V.The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases.Transl Neurodegener2024;13:6 PMCID:PMC10802046

[102] Liao J,An X.Lipoprotein glomerulopathy-like lesions in atherosclerotic mice defected with HDL receptor SR-B1.Front Cardiovasc Med2021;8:734824 PMCID:PMC8531488

[103] Liang X,Li X.Highly sensitive H₂O₂-scavenging nano-bionic system for precise treatment of atherosclerosis.Acta Pharm Sin B2023;13:372-89 PMCID:PMC9939301

[104] Chen F,Han C.Theranostics of atherosclerosis by the indole molecule-templated self-assembly of probucol nanoparticles.J Mater Chem B2021;9:4134-42

[105] Zeng J,Gao Y.Biomimetic ginsenoside Rb1 and probucol Co-assembled nanoparticles for targeted atherosclerosis therapy via inhibition of oxidative stress, inflammation, and lipid deposition.ACS Nano2025;19:22968-87

[106] Fu X,Jiang J.Small molecule-assisted assembly of multifunctional ceria nanozymes for synergistic treatment of atherosclerosis.Nat Commun2022;13:6528 PMCID:PMC9626479

[107] Chen L,Fu X.A targeting mesoporous dopamine nanodrug platform with NIR responsiveness for atherosclerosis improvement.Biomater Adv2022;136:212775

[108] Liang X,Zhang A.Red blood cell biomimetic nanoparticle with anti-inflammatory, anti-oxidative and hypolipidemia effect ameliorated atherosclerosis therapy.Nanomedicine2022;41:102519

[109] Wagle SR,Ionescu CM.Pharmacological and biological study of microencapsulated probucol-secondary bile acid in a diseased mouse model.Pharmaceutics2021;13:1223 PMCID:PMC8400495

[110] Wu Z,Jiang X.Study on the mechanism of probucol nanosuspension on hyperlipidemic pancreatitis and regulation of blood lipid function.J Nanosci Nanotechnol2021;21:1286-92

[111] Wagle SR,Ionescu CM.Probucol-bile acid based nanoparticles protect auditory cells from oxidative stress: an in vitro study.Ther Deliv2024;15:237-52

[112] Okamura T,Arai H.Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022.J Atheroscler Thromb2024;31:641-853

[113] Japan Atherosclerosis Society. Guide for Management of Dyslipidemia for Prevention of Atherosclerotic Cardiovascular Diseases. 2023 Edition (in Japanese).